BACKGROUND: The proinflammatory cytokines tumor necrosis factor alpha (TNF-alpha) and IL-1beta (interleukin 1beta) have a role in neuroinflammation, and functional polymorphisms in the TNF-alpha and IL-1beta genes may affect susceptibility to Parkinson disease (PD). OBJECTIVE: To investigate whether functional DNA polymorphisms of the TNF-alpha and IL-1beta genes affect the risk of PD. DESIGN: Population-based case-control study. SETTING: Three rural California counties (Fresno, Tulare, and Kern). PARTICIPANTS: Two hundred eighty-nine incident idiopathic PD cases and 269 population control subjects, marginally matched by age, sex, and race/ethnicity. MAIN OUTCOME MEASURES: Genotypes of IL-1beta-511 and TNF-alpha-308. RESULTS: We observed a greater than 2-fold increased risk of PD among carriers of the homozygous variant genotype of IL-1beta-511 (odds ratio [OR], 2.26; 95% confidence interval [CI], 1.27-4.02) and the homozygous variant genotype of TNF-alpha-308 (OR, 2.49; 95% CI, 0.90-6.85) and an almost 3-fold increased risk among carriers of the homozygous variant genotype for either or both polymorphisms (OR, 2.92; 95% CI, 1.66-5.16). CONCLUSIONS: A smaller magnitude of PD risk increase among carriers of the heterozygous genotype for either or both polymorphisms suggests a gene-dosing effect (OR, 1.45; 95% CI, 0.97-2.16; P<.001 for trend). Results were not sensitive to exclusion of all nonwhite subjects or to adjustment for nonsteroidal anti-inflammatory drug use or smoking.
BACKGROUND: The proinflammatory cytokines tumor necrosis factor alpha (TNF-alpha) and IL-1beta (interleukin 1beta) have a role in neuroinflammation, and functional polymorphisms in the TNF-alpha and IL-1beta genes may affect susceptibility to Parkinson disease (PD). OBJECTIVE: To investigate whether functional DNA polymorphisms of the TNF-alpha and IL-1beta genes affect the risk of PD. DESIGN: Population-based case-control study. SETTING: Three rural California counties (Fresno, Tulare, and Kern). PARTICIPANTS: Two hundred eighty-nine incident idiopathic PD cases and 269 population control subjects, marginally matched by age, sex, and race/ethnicity. MAIN OUTCOME MEASURES: Genotypes of IL-1beta-511 and TNF-alpha-308. RESULTS: We observed a greater than 2-fold increased risk of PD among carriers of the homozygous variant genotype of IL-1beta-511 (odds ratio [OR], 2.26; 95% confidence interval [CI], 1.27-4.02) and the homozygous variant genotype of TNF-alpha-308 (OR, 2.49; 95% CI, 0.90-6.85) and an almost 3-fold increased risk among carriers of the homozygous variant genotype for either or both polymorphisms (OR, 2.92; 95% CI, 1.66-5.16). CONCLUSIONS: A smaller magnitude of PD risk increase among carriers of the heterozygous genotype for either or both polymorphisms suggests a gene-dosing effect (OR, 1.45; 95% CI, 0.97-2.16; P<.001 for trend). Results were not sensitive to exclusion of all nonwhite subjects or to adjustment for nonsteroidal anti-inflammatory drug use or smoking.
Authors: Simona Perga; Serena Martire; Francesca Montarolo; Nicole D Navone; Andrea Calvo; Giuseppe Fuda; Alberto Marchet; Daniela Leotta; Adriano Chiò; Antonio Bertolotto Journal: Neurotox Res Date: 2017-03-23 Impact factor: 3.911
Authors: Che Brown Hutson; Carlos R Lazo; Farzad Mortazavi; Christopher C Giza; David Hovda; Marie-Francoise Chesselet Journal: J Neurotrauma Date: 2011-09 Impact factor: 5.269
Authors: André Charlett; R John Dobbs; Sylvia M Dobbs; Clive Weller; Mohammad A A Ibrahim; Tracy Dew; Roy Sherwood; Norman L Oxlade; J Malcolm Plant; James Bowthorpe; Andrew J Lawson; Alan Curry; Dale W Peterson; Ingvar T Bjarnason Journal: Gut Pathog Date: 2009-11-26 Impact factor: 4.181
Authors: Miriam E Gerlofs-Nijland; Damien van Berlo; Flemming R Cassee; Roel P F Schins; Kate Wang; Arezoo Campbell Journal: Part Fibre Toxicol Date: 2010-05-17 Impact factor: 9.400
Authors: Marija Bošković; Tomaž Vovk; Marko Saje; Katja Goričar; Vita Dolžan; Blanka Kores Plesničar; Iztok Grabnar Journal: Neurochem Res Date: 2012-12-02 Impact factor: 3.996